yingweiwo

Silodosin (KAD 3213; KMD 3213)

Alias: KAD 3213; KMD 3213; KMD 3213; KAD 3213; KMD-3213; KMD3213; KAD 3213; KAD3213; Silodosin; trade names: Rapaflo; Silodyx, Rapilif; Silodal; Urief; Urorec
Cat No.:V1111 Purity: ≥98%
ilodosin (KMD-3213; KMD3213; KAD3213; KAD-3213; Silodosin; trade names Rapaflo, Silodal, Silodyx, Rapilif, Urief, Urorec) is a highly selective alpha1A/α1A-adrenoceptor antagonist that was approved for the treatment of BPH-benign prostatic hyperplasia.
Silodosin (KAD 3213; KMD 3213)
Silodosin (KAD 3213; KMD 3213) Chemical Structure CAS No.: 160970-54-7
Product category: Adrenergic Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
25mg
50mg
100mg
250mg
500mg
1g
2g
5g
Other Sizes

Other Forms of Silodosin (KAD 3213; KMD 3213):

  • Silodosin-d4 (silodosin d4)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Silodosin (KMD-3213; KMD3213; KAD3213; KAD-3213; Silodosin; trade names Rapaflo, Silodal, Silodyx, Rapilif, Urief, Urorec) is a highly selective alpha1A/α1A-adrenoceptor antagonist that was approved for the treatment of BPH-benign prostatic hyperplasia.

Biological Activity I Assay Protocols (From Reference)
Targets
α1A-AR ( Ki = 0.036 nM ); α1B-AR ( Ki = 21 nM ); α1D-AR ( Ki = 2 nM )
ln Vitro

In vitro activity: Silodosin (KAD 3213; KMD 3213) has a much weaker inhibitory effect on the alpha 1b- and alpha 1d-ARs, but it can inhibit norepinephrine-induced increases in intracellular Ca2+ concentrations in Chinese hamster ovary cells expressing alpha 1a-AR with an IC50 of 0.32 nM[1]. Silodosin has a Ki value of 0.036 nM and potently inhibits the binding of 2-[2-(4-hydroxy-3-[125I]iodophenyl)ethylaminomethyl]-alpha-tetralone to the cloned human alpha 1a-AR, but its potency is 56- and 583-fold lower at the alpha 1b- and alpha 1d-ARs, respectively[2]. Silodosin (0–10 µM; 24 hours) reduces ELK1 gene expression in a dose-dependent manner in all the bladder cancer cell lines[4]. (0–10 µM; 24 hours) reduces the expression of the ELK1 protein in a dose-dependent manner[4]. Silodosin (0-10 µM; 96 hours) barely affects the cell viability of AR-negative 647V or AR-positive UMUC3 or TCCSUP grown in an androgen-depleted environment. On the other hand, silodosin inhibited the growth of UMUC3 cells grown in normal FBS containing androgens (58% reduction at 10 µM)[4].

ln Vivo
Silodosin (intravenous injection; 0.1-0.3mg/kg) decreases the increases in MinP caused by obstruction by 20.7 percent (0.1 mg/kg) and 20.8 percent (0.3 mg/kg) respectively. For the treatment of LUTS/BPH, it may be useful for both storage and voiding dysfunction because it enhances detrusor overactivity and lowers the grade of obstruction[2].
Cell Assay
Cell Line: TCCSUP; UMUC3 and 647V cells
Concentration: 0.1, 0.5, 3.0, or 10 µM
Incubation Time: 24 hours
Result: Decreases ELK1 in bladder cancer cells
Animal Protocol
Sprague Dawley rats
0.1-0.3mg/kg
Intravenous injection
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
The absolute bioavailability is approximately 32%. Following oral administration of silodosin 8 mg once daily in healthy male subjects, Cmax was 61.6 ± 27.54 ng/mL and AUC was 373.4 ± 164.94 ng x hr/mL. The Tmax was 2.6 ± 0.90 hours. Silodosin glucuronide or KMD-3213G, the main metabolite of silodosin, has an AUC three- or four fold higher than for the parent compound. A moderate fat or calorie meal reduces Cmax by 18% to 43% and AUC by 4% to 49%, as well as Tmax by about one hour. However, the US prescribing information recommends drug intake with meals to avoid the potential adverse effects associated with high plasma drug concentrations.
At 10 days following oral administration of radiolabelled silodosin, about 33.5% of the dose was recovered in urine and 54.9% was recovered in feces.
Silodosin has an apparent volume of distribution of 49.5 L.
After intravenous administration, the plasma clearance of silodosin was approximately 10 L/hour.
Metabolism / Metabolites
The main metabolite of silodosin is silodosin glucuronide (KMD-3213G), which is a pharmacologically active metabolite formed by direct glucuronide conjugation mediated by UDP-glucuronosyltransferase 2B7 (UGT2B7). Silodosin glucuronide reaches plasma exposure (AUC) approximately four times greater than that of silodosin. The second major metabolite, KMD-3293, is formed from dehydrogenation catalyzed by alcohol and aldehyde dehydrogenases. KMD-3293 has negligible pharmacological activity and reaches plasma exposures similar to that of silodosin. Silodosin is also metabolized by CYP3A4, which catalyzes the oxidation reaction. Other than glucuronidation, dehydrogenation, and oxidation as its main metabolic pathways, silodosin can also undergo dealkylation (KMD-3289), N-dealkylation, hydroxylation, glucosylation, and sulfate conjugation. Metabolites of silodosin can undergo a series of further metabolic pathways.
Biological Half-Life
The elimination half-life of silodosin is 13.3 ± 8.07 hours. KMD-3213G, the main metabolite of silodosin, has an extended half-life of approximately 24 hours.
Toxicity/Toxicokinetics
Hepatotoxicity
Silodosin has been associated with a low rate of serum aminotransferase elevations (
Likelihood score: E* (unproven but suspected rare cause of clinically apparent liver injury).
Protein Binding
Silodosin is approximately 97% protein bound.
References

[1]. Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010; 4: 291–297.

[2]. Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters.Br J Pharmacol. 2013 May;169(1):230-8.

[3]. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Expert Opin Pharmacother. 2012 Oct;13(14):2085-96.

[4]. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.Am J Cancer Res. 2015 Sep 15;5(10):2959-68. eCollection 2015.

Additional Infomation
Pharmacodynamics
Silodosin is an antagonist of α1-adrenoceptors. It has the highest selectivity for the α1A-adrenoceptor subtype, with a 162-fold greater affinity than α1B-adrenoceptor and about a 50-fold greater affinity than for α1D-adrenoceptor. In clinical trials, silodosin improved maximum urinary flow rate, voiding symptoms, and storage symptoms of benign prostatic hyperplasia. Following oral administration, silodosin had a rapid onset of effect in men, with early effects of relieving lower urinary tract symptoms occurring within two to six hours post-dose. Silodosin inhibited the human ether-a-go-go-related gene (HERG) tail current; however, it has weak cardiovascular effects. As with all α1-adrenoceptor antagonists blocking α1-adrenoceptors in the iris dilator muscle, silodosin may cause intraoperative floppy iris syndrome (IFIS), which is characterized by small pupils and iris billowing during cataract surgery in patients taking α1-AR antagonists.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C25H32F3N3O4
Molecular Weight
495.53
Exact Mass
495.234
Elemental Analysis
C, 60.60; H, 6.51; F, 11.50; N, 8.48; O, 12.91
CAS #
160970-54-7
Related CAS #
Silodosin-d4; 1426173-86-5
PubChem CID
5312125
Appearance
White to off-white solid powder
Density
1.2±0.1 g/cm3
Boiling Point
601.4±55.0 °C at 760 mmHg
Melting Point
107 °C
Flash Point
317.5±31.5 °C
Vapour Pressure
0.0±1.8 mmHg at 25°C
Index of Refraction
1.552
LogP
2.52
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
9
Rotatable Bond Count
13
Heavy Atom Count
35
Complexity
654
Defined Atom Stereocenter Count
1
SMILES
FC(C([H])([H])OC1=C([H])C([H])=C([H])C([H])=C1OC([H])([H])C([H])([H])N([H])[C@]([H])(C([H])([H])[H])C([H])([H])C1C([H])=C(C(N([H])[H])=O)C2=C(C=1[H])C([H])([H])C([H])([H])N2C([H])([H])C([H])([H])C([H])([H])O[H])(F)F
InChi Key
PNCPYILNMDWPEY-QGZVFWFLSA-N
InChi Code
InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
Chemical Name
1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide
Synonyms
KAD 3213; KMD 3213; KMD 3213; KAD 3213; KMD-3213; KMD3213; KAD 3213; KAD3213; Silodosin; trade names: Rapaflo; Silodyx, Rapilif; Silodal; Urief; Urorec
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~99 mg/mL (~199.8 mM)
Water: <1 mg/mL
Ethanol: ~99 mg/mL (~199.8 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.0180 mL 10.0902 mL 20.1804 mL
5 mM 0.4036 mL 2.0180 mL 4.0361 mL
10 mM 0.2018 mL 1.0090 mL 2.0180 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Randomized comparative clinical study on alpha 1 receptor blockers silodosin and urapidil for female lower urinary tract symptoms
CTID: UMIN000011755
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2013-09-13
Randomized comparative clinical study on alpha 1 receptor blockers silodosin and urapidil for female lower urinary tract symptoms
CTID: UMIN000011755
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2013-09-13
Comparative Study of Early Efficacy of Once-Daily Dosing between Silodosin 4mg and Tamsulosin 0.2mg for Voiding Symptoms Associated with Benign Prostatic Hyperplasia
CTID: UMIN000011556
Phase:    Status: Complete: follow-up complete
Date: 2013-08-26
A study of the safety of alpha1-blocker silodosin in adult women
CTID: UMIN000009102
Phase: Phase I    Status: Complete: follow-up complete
Date: 2012-10-12
Comparative study of safety and efficacy due to the dose change from 4 mg to 8 mg silodosin for benign prostatic hyperplasia with lower urinary tract symptoms
CTID: UMIN000008483
Phase:    Status: Complete: follow-up complete
Date: 2012-09-01
View More

Comparison of the long-term efficacy of silodosin and tamsulodin for the tratment of benign prostatic hyperplasia
CTID: UMIN000008538
Phase: Phase IV    Status: Complete: follow-up complete
Date: 2012-08-01


A COMPARATIVE STUDY ON THE CLINICAL EFFECTS OF SILODOSIN AND NAFTOPIDIL IN JAPANESE PATIENTS WITH LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
CTID: UMIN000008331
Phase:    Status: Complete: follow-up complete
Date: 2012-07-03
Efficacy and safety of silodosin on lower urinary tract symptoms (LUTS) in patients with Parkinson's disease
CTID: UMIN000008138
Phase:    Status: Complete: follow-up complete
Date: 2012-07-01
Efficacy of silodosin in benign prostatic hyperplasia with overactive bladder.
CTID: UMIN000007917
Phase:    Status: Recruiting
Date: 2012-05-09
The effect of alpha1-AR antagonists for lower urinary tract symptoms in patients undergoing prostate 125I brachytherapy for prostate carcinoma
CTID: UMIN000005786
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2011-06-16
The clinical study for evaluating the early efficacy and safty of alpha-1-adrenoreceptor antagonists in patient with benign prostatic hyperplasia.
CTID: UMIN000005151
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2011-03-01
Silodosin 4mg versus tamsulosin 0.2mg once daily; randomized crossover study
CTID: UMIN000004918
Phase:    Status: Complete: follow-up complete
Date: 2011-01-21
The effects of selective alpha-1-adrenergic receptor antagonists in patients with lower urinary tract symptoms caused by benign prostatic hyperplasiawho failed to obtain sufficient efficacy by previous alpha-1-blockades. . A comparison of Naftopidil or Silodosin.
CTID: UMIN000003609
Phase:    Status: Pending
Date: 2010-05-16
CLSS-based assessment of alfa-adrenoceptor blockers for male LUTS (CLAM-STUDY)
CTID: UMIN000003125
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2010-02-01
Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasia
CTID: UMIN000002188
Phase:    Status: Pending
Date: 2009-08-01
Effect of alfha1-adrenoceptor antagonist in lower urinary tract symptoms after high dose brachytherapy for prostate cancer
CTID: UMIN000002066
Phase:    Status: Pending
Date: 2009-06-15
Randomized clinical study of silodosin vs propiverine for men aged 50 or older with overactivebladder and 20 to 30ml of prostate volume
CTID: UMIN000001423
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2008-10-14

Biological Data
  • Effects of silodosin on ELK1 in bladder cancer cells. Am J Cancer Res . 2015 Sep 15;5(10):2959-68. eCollection 2015.
  • Effects of silodosin on bladder cancer cell growth. MTT assay in TCCSUP (A), UMUC3 (B, D), 647V (C), and UMUC3-ELK1-shRNA (E). Am J Cancer Res . 2015 Sep 15;5(10):2959-68. eCollection 2015.
  • Representative original ureteral pressure traces recorded after partial obstruction and administration of silodosin (A), tamsulosin (B) and prazosin (C) given at the maximal tested dose. Br J Pharmacol . 2013 May;169(1):230-8.
  • Ureter pressure parameters in vivo. Inhibitory effects of different doses of silodosin (black bars), tamsulosin (grey bars) or prazosin (white bars) on minimal (A) and maximal (B) ureter pressure, and AUC (C). Br J Pharmacol . 2013 May;169(1):230-8.
Contact Us